Roche's experimental multiple sclerosis drug achieved its main goal in one of two key late-stage trials testing it against ...

Two Phase 3 trials testing the investigational oral therapy fenebrutinib in people with multiple sclerosis (MS) have hit ...

By Ludwig Burger FRANKFURT (Reuters) -Swiss drugmaker Roche said on Monday that a late-stage trial testing its multiple ...

Roche has built the evidence for its oral BTK inhibitor fenebrutinib in multiple sclerosis (MS) with two phase 3 readouts ...

An experimental drug compound could be a promising treatment for harmful diabetes complications, per a new study in lab mice ...

Roche's late-stage trial of fenebrutinib, a multiple sclerosis drug candidate, met its primary goal. The trial demonstrated a significant reduction in annualized relapse rates compared to ...

Genentech, a member of the Roche Group, has announced positive results from the first of two phase 3 trials investigating ...

At AAPS PharmSci 360 2025, Elly Zhou says digital twins helped forecast the effects of drugs on human drugs via a digital control arm.

If Roche's fenebrutinib got the FDA go-ahead, it would become the first BTK inhibitor to gain approval in both RMS and PPMS.

Case Western University scientists were gifted $2.5 million to advance MS research into whether glial cells can be targeted to repair myelin.

The virus that causes glandular fever may be an unsuspected cause of several autoimmune conditions, lending hope for new ...